NBP607-QIV

· SK Chemicals Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NBP607-QIV, covering 2020-05-08 to 2022-05-11. Get the full timeline:

Most recent: Clinical Trial Update: Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months [Phase 3]